OverviewSuggest Edit

Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics. Zymeworks is committed to developing best-in-class protein therapeutics for the treatment of cancer, autoimmune and inflammatory diseases.

The Company's approach combines proprietary molecular modeling and simulation software with high-performance computing to create an environment for in silico experimentation and predictive protein optimization. Using this approach Zymeworks has developed multiple platform technologies to advance the field of biologics drug discovery and optimization.

TypePublic
Founded2003
HQVancouver, CA
Websitezymeworks.com
Employee Ratings4.7

Latest Updates

Employees (est.) (Dec 2021)455(+19%)
Job Openings7
Share Price (Jan 2022)$10
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Zymeworks

Ali Tehrani

Ali Tehrani

President & Chief Executive Officer
Neil Klompas

Neil Klompas

Executive Vice President, Business Operations and Chief Financial Officer
Tony Polverino

Tony Polverino

EVP, Early Development & CSO
Surjit Dixit

Surjit Dixit

Vice President, Technology
John Babcook

John Babcook

SVP, Discovery Research
James Priour

James Priour

Chief Commercial Officer
Show more

Zymeworks Office Locations

Zymeworks has offices in Vancouver and Seattle
Vancouver, CA (HQ)
1385 W 8th Ave #540
Seattle, WA, US
1215 4th Ave #2100
Show all (2)

Zymeworks Financials and Metrics

Zymeworks Revenue

Market capitalization (25-Jan-2022)

465.5m

Closing stock price (25-Jan-2022)

10.0
Zymeworks's current market capitalization is $465.5 m.
Show all financial metrics

Zymeworks Cybersecurity Score

Cybersecurity ratingPremium dataset

B

84/100

SecurityScorecard logo

Zymeworks Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Zymeworks Online and Social Media Presence

Embed Graph

Zymeworks News and Updates

HER2 Targeting Therapies Market Assessment 2021-2030 with Profiles of AstraZeneca, Boehringer Ingelheim, GSK, MacroGenics, Pfizer, Puma Biotechnology, Roche, Seagen, Triumvira Immunologics, Zymeworks

Dublin, Sept. 29, 2021 (GLOBE NEWSWIRE) -- The "HER2 Targeting Therapies Market by Target Disease Indication, Type of Molecule, Type of Therapy and Route of Administration, Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2030" report has been added to ResearchAndMarkets.com's …

ImmunoPrecise Announces New Multi-Specific SARS-CoV-2 Antibody Collaboration with Zymeworks

VICTORIA, BC, Sept. 17, 2020 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, announce a research collaboration with Zymeworks Inc., giving...

Zymeworks Blogs

Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2022

New Chair and CEO, Mr. Kenneth Galbraith , outlines strategic priorities for 2022 and 2023 across key clinical development activities for zanidatamab and ZW49, preclinical R&D pipeline, collaborations and partnerships Further changes to leadership team announced today in connection with Mr.

Zymeworks Reports Inducement Grant Under New York Stock Exchange Listed Company Manual Rule

VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Jan. 15, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported, as required by the New York Stock Exchange Listed Company Manual Rule 303A.08 (the “NYSE

Zymeworks to Present at 40th Annual J.P. Morgan Healthcare Conference

Zymeworks to Present at 40th Annual J.P. Morgan Healthcare Conference Content Import Thu, 01/06/2022 - 08:31 Zymeworks to Present at 40th Annual J.P. Morgan Healthcare Conference 01/06/2022 at 8:30 AM EST This release is a backfill from a News Wire …

Zymeworks Names Biotechnology Industry Leader Kenneth Galbraith as Chair and CEO to Succeed Dr. Ali Tehrani

Zymeworks Names Biotechnology Industry Leader Kenneth Galbraith as Chair and CEO to Succeed Dr. Ali Tehrani Content Import Wed, 01/05/2022 - 16:31 Zymeworks Names Biotechnology Industry Leader Kenneth Galbraith as Chair and CEO to Succeed Dr. Ali Tehrani 01/05/2022 at 4:30 P…

Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in Asia in Collaboration with BeiGene and Associated Milestone Payment

First patient dosed in South Korea under Zymeworks and BeiGene collaboration agreement HERIZON-GEA-01 enrollment progresses with multiple active sites and continued global recruitment Zymeworks to receive US$8MM development milestone payment from BeiGene   VANCOUVER, British Columbia --(BUSINESS

Zanidatamab Data Presented at the San Antonio Breast Cancer Symposium (SABCS) Demonstrate Encouraging Antitumor Activity in Heavily Pretreated Patients with HER2-Positive Breast Cancer

Zanidatamab Data Presented at the San Antonio Breast Cancer Symposium (SABCS) Demonstrate Encouraging Antitumor Activity in Heavily Pretreated Patients with HER2-Positive Breast Cancer Content Import Wed, 12/08/2021 - 18:00 Zanidatamab Data Presented at the San Antonio Breast Cancer Sympos…
Show more

Zymeworks Frequently Asked Questions

  • When was Zymeworks founded?

    Zymeworks was founded in 2003.

  • Who are Zymeworks key executives?

    Zymeworks's key executives are Ali Tehrani, Neil Klompas and Tony Polverino.

  • How many employees does Zymeworks have?

    Zymeworks has 455 employees.

  • Who are Zymeworks competitors?

    Competitors of Zymeworks include NovoCure, Neovii and SQZ Biotech.

  • Where is Zymeworks headquarters?

    Zymeworks headquarters is located at 1385 W 8th Ave #540, Vancouver.

  • Where are Zymeworks offices?

    Zymeworks has offices in Vancouver and Seattle.

  • How many offices does Zymeworks have?

    Zymeworks has 2 offices.